Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Net Cash Flow: 2020-2024

Historic Net Cash Flow for Oncology Institute (TOI) over the last 5 years, with FY2024 value amounting to $16.2 million.

  • Oncology Institute's Net Cash Flow fell 12399.34% to -$2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$19.9 million, marking a year-over-year decrease of 20031.71%. This contributed to the annual value of $16.2 million for FY2024, which is 1692.68% down from last year.
  • According to the latest figures from FY2024, Oncology Institute's Net Cash Flow is $16.2 million, which was down 1692.68% from $19.5 million recorded in FY2023.
  • Over the past 5 years, Oncology Institute's Net Cash Flow peaked at $109.2 million during FY2021, and registered a low of -$101.2 million during FY2022.
  • Its 5-year average for Net Cash Flow is $9.4 million, with a median of $16.2 million in 2024.
  • Its Net Cash Flow has fluctuated over the past 5 years, first soared by 297364.86% in 2021, then crashed by 19266.14% in 2022.
  • Oncology Institute's Net Cash Flow (Annual) stood at $3.6 million in 2020, then skyrocketed by 2973.65% to $109.2 million in 2021, then crashed by 192.66% to -$101.2 million in 2022, then soared by 119.25% to $19.5 million in 2023, then fell by 16.93% to $16.2 million in 2024.
  • Its Net Cash Flow stands at $16.2 million for FY2024, versus $19.5 million for FY2023 and -$101.2 million for FY2022.